Treating Immunocompromised Patients with Hepatitis B
JAN 15, 2019 | CONTAGION® EDITORIAL STAFF
In a presentation at ID Week 2018, Kenneth Sherman, MD, Gould Professor of Medicine at the University of Cincinnati College of Medicine, discussed hepatitis B infections in immunocompromised patients and what clinicians should expect to see in the future for hepatitis B treatment.
Interview transcript: (modified slightly for readability)
Contagion®: What should clinicians know about treating immunocompromised patients with hepatitis B?
Dr. Sherman: Immunocompromised patients with hepatitis B are at risk for increased rates of disease progression, related to the presence of hepatitis B. Those patients have higher levels of ALT which reflects higher levels of inflammation which leads to higher rates of hepatic fibrosis.
Therefore, at any given time in the course of the disease, those patients will end up with more likelihood of having eventually cirrhosis and all of the complications that accompany cirrhosis. Often these may be unrecognized until the patient presents with decompensated liver disease
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Big advances in treatment can't make up for an inability to stop new infections, which number 5,000 per day worldwide.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512